[
    [
        {
            "time": "",
            "original_text": "智飞生物2018年净利润同比增长235.75% 拟每10股派5元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2018年",
                    "净利润",
                    "同比增长",
                    "235.75%",
                    "派息"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物2018年净利润同比增长235.75% 拟每10股派5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[快讯]智飞生物公布第一季度业绩预告",
            "features": {
                "keywords": [
                    "智飞生物",
                    "第一季度",
                    "业绩预告"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[快讯]智飞生物公布第一季度业绩预告",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：2018年净利增235.7% 拟10派5元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2018年",
                    "净利",
                    "增长",
                    "235.7%",
                    "派息"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：2018年净利增235.7% 拟10派5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物(300122.SZ)2018年净利润升235.75%至14.51亿元 拟10派5元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2018年",
                    "净利润",
                    "上升",
                    "235.75%",
                    "14.51亿元",
                    "派息"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物(300122.SZ)2018年净利润升235.75%至14.51亿元 拟10派5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物年报：2018年净利增235.75%，拟10派5元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2018年",
                    "净利",
                    "增长",
                    "235.75%",
                    "派息"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物年报：2018年净利增235.75%，拟10派5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "最新药企身价排行榜出炉 千亿市值上市公司仅剩三席",
            "features": {
                "keywords": [
                    "药企",
                    "身价排行榜",
                    "千亿市值",
                    "上市公司"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "最新药企身价排行榜出炉 千亿市值上市公司仅剩三席",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "智飞生物AC-Hib疫苗因批文到期暂停生产 知情人称企业已备足近600万支产品 经营问题",
            "features": {
                "keywords": [
                    "智飞生物",
                    "AC-Hib疫苗",
                    "批文到期",
                    "暂停生产",
                    "经营问题"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物AC-Hib疫苗因批文到期暂停生产 知情人称企业已备足近600万支产品 经营问题",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "A股“疫苗之王”跌停 智飞生物独家疫苗注册未获批 业绩将大受影响？",
            "features": {
                "keywords": [
                    "A股",
                    "疫苗之王",
                    "跌停",
                    "智飞生物",
                    "独家疫苗",
                    "注册未获批",
                    "业绩影响"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股“疫苗之王”跌停 智飞生物独家疫苗注册未获批 业绩将大受影响？",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]